OPPORTUNITY FOR INNOVATION IN ASPIRIN DELIVERY
According to aspirin professional class labeling, enteric coated aspirin products are erratically absorbed from the GI tract1
Plain aspirin is associated with local GI injury, which can be asymptomatic2
In patients using aspirin for secondary prevention, discontinuation led to a 46% higher rate of cardiovascular events3
There hasn’t been innovation in the mechanism of
aspirin delivery in over 50 years
References:
- CFR — Code of Federal Regulations Title 21. Internal Analgesic, Antipyretic, and Antirhreumatic Drug Products for Over-the-Counter Human Use. Food and Drug Administration; US Dept of Health and Human Services; 2015.
- Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137-146.
- Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation. 2017;136(13):1183-1192.